Phibro Animal Health Corporatio

Valuation Analysis

About the Company

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health an

Phibro Animal Health Corporatio Stock at a Glance

Phibro Animal Health Corporatio (PAHC) is currently trading at $31.53 with a market capitalization of $1.3B. The trailing P/E ratio stands at 13.53x, with a forward P/E of 9.43x. The 52-week range spans from $23.57 to $60.08; the current price is 47.5% below the yearly high. Year-over-year revenue growth stands at +10.3%. The net profit margin stands at 6.35%.

💰 Dividend

Phibro Animal Health Corporatio pays an annual dividend of $0.48 per share, representing a yield of 1.52%. The payout ratio stands at 20.6%.

📊 Analyst Rating

5 analysts rate Phibro Animal Health Corporatio (PAHC) on consensus: Hold. The average price target is $45.60, implying +44.62% from the current price. Analyst price targets range from $38.00 to $58.00.

Phibro Animal Health Corporatio: The Investment Case in Detail

Phibro Animal Health Corporatio (PAHC) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 10.3% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Return on equity of 30.34% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

The Bear Case

The debt-to-equity ratio of 217.97% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valuation in Context

The EV/EBITDA multiple of 8.47x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 9.43x is meaningfully below the trailing 13.53x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 44.62% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (6.22%), higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Phibro Animal Health Corporatio?

Compare top-rated brokers — low fees, trusted providers, fully regulated.